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Abstract:  In  contrast  to  arsenic  (As)  poisoning  caused  by  naturally  occurring  inorganic 
arsenic-contaminated water consumption, coal arsenic poisoning (CAP) induced by elevated 
arsenic  exposure  from  coal  combustion  has  rarely  been  reported.  In  this  study,  the 
concentrations and distributions of urinary arsenic metabolites in 57 volunteers (36 subjects 
with skin lesions and 21 subjects without skin lesions), who had been exposed to elevated 
levels of arsenic present in coal in Changshapu village in the south of Shaanxi Province 
(China),  were  reported.  The  urinary  arsenic  species,  including  inorganic  arsenic  (iAs) 
[arsenite (iAs
III) and arsenate (iAs
V)], monomethylarsonic acid (MMA
V) and dimethylarsinic 
acid  (DMA
V),  were  determined  by  high-performance  liquid  chromatography  (HPLC) 
combined  with  inductively  coupled  plasma  mass  spectroscopy  (ICP-MS).  The  relative 
distributions of arsenic species, the primary methylation index (PMI = MMA
V/iAs) and the 
secondary  methylation  index  (SMI  =  DMA
V/MMA
V)  were  calculated  to  assess  the 
metabolism  of  arsenic.  Subjects  with  skin  lesions  had  a  higher  concentration  of  urinary 
arsenic and a lower arsenic methylation capability than subjects without skin lesions. Women 
had a significantly higher methylation capability of arsenic than men, as defined by a higher 
percent DMA
V and SMI in urine among women, which was the one possible interpretation of 
women with a higher concentration of urinary arsenic but lower susceptibility to skin lesions. 
The  findings  suggested  that  not  only  the  dose  of  arsenic  exposure  but  also  the  arsenic 
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methylation capability have an impact on the individual susceptibility to skin lesions induced 
by coal arsenic exposure.  
Keywords:  arsenic  (As);  urinary  metabolites;  methylation  capability;  skin  lesions;  
coal arsenic poisoning (CAP); China 
 
1. Introduction 
Arsenic (As) is a ubiquitous element in environment. An established association between human 
chronic arsenic exposure and a variety of health outcomes, including skin diseases, diabetes, peripheral 
vascular disease and kinds of cancers [1-5], has been known for many years. It was reported that there 
was a wide variation in susceptibility to arsenic health outcomes, which may be, to some extent, 
related to variations in arsenic metabolism [2].  
The metabolism of arsenic in humans occurs through reduction and oxidative methylation catalyzed 
by reductases and methyltransferases [6]. First, pentavalent arsenate is reduced to trivalent arsenite in the 
blood,  and  then  inorganic  arsenic  (iAs)  is  transformed  into  monomethylarsinic  acid  (MMA
V)  and 
dimethylarsinic acid (DMA
V). Although MMA
V and DMA
V are less toxic than iAs [6,7], the existence of 
trivalent intermediates, monomethylarsonous acid (MMA
III) and dimethylarsinous acid (DMA
III) during 
the arsenic metabolism process has been confirmed [8]. They are formed by the reduction of MMA
V and 
DMA
V and are more toxic than iAs. Petrick and his colleagues have proposed the following order of 
toxicity of arsenicals in Chang human hepatocytes: MMA
III > arsenite > arsenate > MMA
V = DMA
V [7]. 
Therefore, it is considered that methylation is the key to understanding the biotransformation of arsenic 
and may be related to the mechanism of arsenic toxicity. 
Urinary arsenic is generally used as the main biomarker of exposure and is regarded as the most 
reliable indicator of recent exposure to iAs [9]. A positive correlation between total daily intake of 
arsenic from water and total arsenic concentration in urine has been found (r = 0.5, p < 0.001) in a 
study from Mexico [10]. The relative distributions of urinary iAs, MMA and DMA have been used as 
measures  of  human  methylation  capability  [1,9,11,12].  Besides,  primary  methylation  index  (PMI, 
defined  as  MMA/iAs)  and  secondary  methylation  index  (SMI,  defined  as  DMA/MMA)  has  been 
applied  to  assess  the  first  and  second  methylation  step,  respectively  [1,9,11].  Several  studies  of 
arsenism induced by arsenic-contaminated water consumption from Bangladesh, Taiwan and Mexico, 
have shown an increasing prevalence of arsenic-associated toxic effects with increasing percentage of 
iAs and MMA
V and decreasing percentage of DMA
V and SMI [1-3,11]. 
Worldwide, to date coal arsenic poisoning (CAP) only has been found in China. Shaanxi Province is 
the second highest CAP-prevalent area next to Guizhou province in China. CAP is caused by arsenic 
exposure from coal confusion and the coal arsenic concentration is found to be 27.95–475.10 mg/kg 
(mean: 222.40 mg/kg) in the south of Shaanxi Province [13]. It is much higher than the average arsenic 
content in coal in the World (9.0 mg/kg) or in China (4.5 mg/kg) [14,15]. Coal is burnt indoors, in stoves 
without a chimney, for cooking and heating; therefore, indoor air and food were found to be polluted by 
smoke with high levels of arsenic. The arsenic content of indoor air was 6.32 ±  9.95 μg/m
3 [13], being 
2.3  times  higher  than  the  maximum  levels  of  arsenic  in  the  air  (3  μg/m
3)  [16].  The  average Int. J. Environ. Res. Public Health 2011, 8                 
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concentrations  of  arsenic  in  stove-dried  corn  and  stove-dried  chili  were  0.76  ±   0.72  mg/kg  and  
0.96  ±   1.41  mg/kg  [13],  respectively,  which  are  approximately  3  and  19  times  higher  than  the 
maximum  levels  of  arsenic  allowed  in  foods  in  China  (0.2  and  0.05  mg/kg,  respectively)  [17]. 
Moreover, arsenic concentrations in drinking water [13] were less than 10 μg/L the drinking water 
standard in China [18]. The CAP situation in Shaanxi Province is serious and the rate of prevalence of 
CAP ranges from 19.75–70.7% in different villages [19]. In contrast to arsenic (As) poisoning caused 
by naturally occurring inorganic arsenic-contaminated water consumption, CAP induced by elevated 
arsenic exposure from coal combustion has been rarely reported, especially in the field of evaluating 
the association between urinary arsenic profiles and the health outcomes of human. 
Within the context of the perspectives mentioned above, the objectives of our study were: (1) to 
investigate the profile of urinary arsenic metabolites in residents exposed to coal arsenic in the south of 
Shaanxi Province (China); (2) to find out the relationship between urinary arsenic metabolites and skin 
lesions induced by chronic arsenic exposure; (3) to evaluate the effect of sex and age on urinary 
arsenic metabolites and arsenic methylation capability.  
2. Experimental Section  
2.1. Study Area 
The study was conducted in a typical CAP epidemic village, namely Changshapu, in Pingli County 
of Ankang City located in the south of Shaanxi Province (China) (Figure 1).  
Figure 1. Map of the study area. 
 
Changshapu is a poor small village with an agrarian economy. The climate is usually wet and 
humid. Therefore, for their daily cooking, heating and indoor drying of grains (corn and chili) the 
villagers usually burn stone-like coal, which contains a very low content of carbon and a high content 
of arsenic. The mean concentration of arsenic in the stone-like coal used in Changshapu village was 
278 mg/kg [20]. In Changshapu village, the stone-like coal mainly originated from the same colliery Int. J. Environ. Res. Public Health 2011, 8                 
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near  the  village,  which  has  been  mined  for  100  years.  Therefore,  all  the  residents  had  life-long 
exposures to arsenic polluted air and food.  
2.2. Study Population 
In  Changshapu  village,  there  were  335  registered  permanent  residents,  185  (55%)  men  and  
150  (45%)  women.  Most  of  the  young  people  (18  to  40  years  old)  worked  far  away  from  their 
hometown for most of the year. Therefore, 57 volunteers above eighteen years old participated in this 
study. They had always lived in Changshapu village since when they were born and had suffered  
life-long exposure to elevated arsenic concentrations in the environment. In order to identify the cases 
of skin lesions induced by arsenic exposure, detailed physical examinations were conducted by trained 
medical doctors according to the Standards of Diagnosis for Endemic Arsenism [21]. In the standards, 
palms of the hands, soles of the feet and parts of the body trunk were examined for symptoms of skin 
lesions,  including  pigmentation,  hyperpigmentation  (melanosis),  hypopigmentation,  keratosis, 
hyperkeratosis,  skin  ulceration  and  skin  cancers  (Bowen  disease),  and  each  category  of  clinical 
symptoms was assigned a rank. The arsenism patients were then classified as “suspected,” “mild,” 
“moderate,” “severe,” and “skin cancer” with increasing ranking order. There was only pigmentation 
and hypopigmentation cases but no keratosis and skin cancers cases among the 57 volunteers. The 
cases with “suspected”, “mild”, “moderate” and “severe” arsenism were classified as “subjects with 
skin lesions” and others not showing skin lesions were classified “subjects without skin lesions”. The 
volunteers included 36 subjects with skin lesions (12 females and 24 males) and 21 subjects without 
skin lesions (12 females and nine males).  
According to the World Medical Association Declaration of Helsinki Ethical Principles for Medical 
Research Involving Human Subjects [22], all 57 of the volunteers were gave informed consent before 
participating. The data of personal information, including sex and age, were obtained by questionnaire. 
2.3. Sample Collection  
The information about the heating period in Changshapu village was achieved by inquiry. The 
residents in Changshapu village started using stone-like coal for heating from November to March 
each year. Therefore, sample collection was taken in the middle of March, 2008, which was the end of 
the heating period of Changshapu. According to the IUPAC guidelines of sample collection for trace 
elements in blood and urine [23], 10 mL of first-morning void urine were obtained in polypropylene 
tubes and kept in a box with ice. The box was covered to avoid exposure to light. Within 8 h, the urine 
samples were transported to the local Center of Disease Control and stored at −20 °C . Within five days, 
all urine samples were transported to the Institute of Geographical Sciences and Natural Resources 
Research, Chinese Academy of Science for analysis. 
2.4. Reagents and Standards 
The  standard  solutions  of  arsenious  acid  (GBW08666,  AsO3
3−),  monomethylarsonic  acid 
(GBW08668, CH3AsO3
2−) and dimethylarsinic acid (GBW08669, C2H7AsO2) were bought from the 
National Center of Standard Reference Materials (Beijing, China). The standard solution of arsenate Int. J. Environ. Res. Public Health 2011, 8                 
 
 
1995 
(1,000-mg/L, Na3AsO4) was from Perkin Elmer Ltd Company (Beijing, China). All other reagents 
used in this study were guaranteed (the highest grade commercially available in China).  
2.5. Determination of Arsenic Metabolites 
Quantitative  determination  of  urinary  arsenic  species  was  performed  as  described  
previously [24,25]. The arsenic species (iAs
III, iAs
V, MMA
V and DMA
V) in urine were determined by 
using  high-performance  liquid  chromatography  (HPLC)  (PerkinElmer  200  series,  USA)  combined 
with inductively coupled plasma mass spectroscopy (ICP-MS) (Elan DRC-e, PerkinElmer, USA). The 
parameters of the instruments for the chromatographic separation and detection were listed in Table 1. 
Separation was performed on a PRP-X100 anion exchange column (150 mm ×  4.10 mm, 5 μm particle 
size, Hamilton) and a guard column (10 μm particle size, 20 mm length, 2.0 mm i.d., Hamilton). The 
mobile phase contained 20 mM Ammonium phosphate (dibasic). 15% ammonium hydroxide was used 
to adjust the pH to 6.0. The mobile phase was filtered through a 0.45 μm membrane and sonicated for 
10 min before use in HPLC separation.  
Table 1. Operating conditions of the HPLC-ICP-MS for arsenic speciation in urine. 
HPLC parameters 
Column  Anion Exchange, Hamilton PRP-X100 
(15 ×  4.1 mm i.d.) 
Mobile phase  20 mM Ammonium Phosphate (dibasic);  
pH 6.0 
Column temperature  Ambient 
Flow rate  1.2 mL/min 
Sample injection volume  20 μL 
Runtime  8 min 
ICP Operating parameters 
Plasma power  1,350 w 
Auxiliary gas flow  1.2 L/min 
Plasma gas flow  15 L/min 
Nebulizer gas flow  1 l L/min 
DRC gas flow  0.45 L/min 
RPq  0.5 
Mass spectroscopy acquisition 
Monitored signal  m/z 91 
Dwell time   250 ms 
Scan mode  Peak hopping 
Sweeps/reading  1 
Readings/replicate  1,200 
Replicates  3 
Briefly, 1-mL urine was passed through a filter with 0.22 μm pore size and 13 mm diameter. Then, 
each sample was determined by HPLC in triplicate. A typical chromatogram of four arsenic species in Int. J. Environ. Res. Public Health 2011, 8                 
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standard mixture in deionized water was shown in Figure 2(A) and in a urine sample in Figure 2(B). 
The retention times of iAs
III, iAs
V, MMA
V and DMA
V were 1.5, 1.8, 2.4 and 5.7 min, respectively. 
Figure 2. Chromatogram of four arsenic species (A) in standard mixture in deionized water; 
(B) in a urine sample. 
 
 
The Elan DRC-e ICP-MS system was operated in the dynamic reaction cell (DRC) mode. Oxygen 
was used as the reaction gas. Peak hopping scan mode was used to monitor AsO
+ at 91 amu. The limits 
of detection were 0.163 μg/L for iAs
III, 0.33 μg/L for iAs
V, 0.15μg/L for MMA
V and 0.146 μg/L for  
DMA
V. If the concentrations of iAs
V in urinary were lower than the limits of detection, the values were 
recorded as half of the detection limit. The reliability of the arsenic species separation was evaluated 
by the analytical recoveries of added arsenic species. Spiking the recoveries of iAs
III, iAs
V, MMA
V and 
DMA
V were 81–95%, 83–98%, 82–102% and 94–110%, respectively. 
2.6. Creatinine in Urine 
Creatinine was necessary for the correction of arsenic concentrations in urinary volume [26]. The 
concentrations of creatinine were determined by enzyme reaction with a commercial kit (Wako Pure 
Chemical Industries, Ltd., Japan). Int. J. Environ. Res. Public Health 2011, 8                 
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2.7. Statistical Analysis 
The  total  arsenic concentration (TAs), the percentages of  the four arsenic species, the  primary 
arsenic methylation index (PMI) and the secondary arsenic methylation index (SMI) are calculated  
as follows: 
TAs = iAs
III + iAs
 V + MMA
 V + DMA
 V  (1)  
Percentage of Arsenic species (iAs
III, iAs
 V, MMA
 V, DMA
 V) = Arsenic species/TAs*100%;  (2)  
PMI = MMA
 V /(iAs
III + iAs
 V)  (3)  
SMI = DMA
 V /MMA
 V  (4)  
Data analysis was performed by using SPSS software (version 11.5, SPSS Inc., Chicago, IL, USA). 
The  concentrations  and  percentages  of  arsenic  species,  as  well  as  PMI  and  SMI,  were  first  
log-transformed to meet the requirement of equal variance and normal distribution of residuals. The 
values were transformed back to the arithmetic scale for reporting purposes. The independent samples 
t-test was used to reflect the difference of the log-transformed data of urinary arsenic species and 
arsenic methylation capability indexes. Spearman’s correlation was used to analyze the relationships 
between varies urinary arsenic species and age. The statistical significance was set at p < 0.01 and  
p < 0.05, respectively. 
3. Results and Discussion 
3.1. Urinary Arsenic Metabolites of the Study Population 
The  findings  regarding  the  content  of  arsenic  metabolites  in  urine  and  the  arsenic  methylation 
capability indexes of the 57 volunteers were presented in Table 2. The concentrations of urinary iAs
III, 
iAs
V, MMA
V, DMA
V and TAs were 2.97, 0.9, 4.69, 23.41 and 31.97 μg/g Cr, respectively. DMA
V was 
the major arsenic species in urine (72.38%), followed by MMA
V (14.50%), iAs
III (9.17%) and iAs
V 
(2.78%).  Other  two  arsenic  methylation  capability  indexes,  namely  PMI  and  SMI,  were  1.32  and  
4.99, respectively. 
3.2. Urinary Arsenic Metabolites between Subjects with and without Skin Lesions  
The concentrations of all of the urinary arsenic species and TAs of subjects with skin lesions were 
significantly higher than that of subjects without skin lesions (Table 2). It was shown that the subjects 
with skin lesions excreted more arsenic in urine than subjects without skin lesions, which may indicate 
a higher recent arsenic exposure in subjects with skin lesions.  
The percent DMA
V and the SMI were significantly lower, while the percent iAs
V was significantly 
higher of the subjects with skin lesions than that of the subjects without skin lesions. A higher percent 
iAs
III and percent MMA
V and a lower PMI were also observed in subjects with skin lesions; however, 
the difference did not reach statistical significance. These data suggested that the arsenic methylation 
capability, especially the secondary methylation capability in subjects with skin lesions were lower 
than in subjects without skin lesions. Int. J. Environ. Res. Public Health 2011, 8                 
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Table 2. Concentrations and percentages of arsenic species in urine of the volunteers (N = 57). 
Metabolites and  
Methylation index 
Total subjects  
(n = 57) GM (95% CI) 
Subjects without skin lesions 
(n = 21) GM (95% CI) 
Subjects with skin lesion 
(n = 36) GM (95% CI) 
TAs (μg/g Cr)  31.97 (34.35–47.54)  26.0 (18.68–63.9)  36.09
 ** (35.1–49.82) 
iAs
III (μg/g Cr)  2.97 (3.33–5.05)  2.33 (1.83–2.97)  3.41
 ** (2.7–4.3) 
MMA
V(μg/g Cr)  4.69 (3.99–5.51)  3.47 (2.78–4.35)  5.59
 *** (4.55–6.85) 
DMA
V (μg/g Cr)  23.41 (23.49–32.57)  19.67 (15.29–25.29)  25.91
 * (21.29–31.54) 
iAs
V (μg/g Cr)  0.9 (0.71–1.14)  0.57 (0.40–0.79)  1.18
 *** (0.88–1.59) 
Percent iAs
III (%)  9.17 (8.31–10.12)  8.98 (8–10.08)  9.28 (8.02–10.73) 
Percent MMA
V (%)  14.50 (13.4–15.67)  13.36 (11.53–15.49)  15.21 (13.87–16.65) 
Percent DMA
V (%)  72.38 (70.57–74.24)  75.65 (73.49–77.87)  70.54
 *** (68.15–73.03) 
Percent iAs
V (%)  2.78 (2.34–3.31)  2.18 (1.72–2.76)  3.21
 ** (2.54–4.06) 
PMI  1.32 (1.14–1.53)  1.37 (1.11–1.69)  1.29 (1.05–1.59) 
SMI  4.99 (4.54–5.49)  5.66 (4.77–6.72)  4.64
 ** (4.15–5.18) 
Abbreviations: CI, confidence interval; Cr, creatinine; GM, geometric mean. 
*** The difference is significant at p < 0.01 compared with subjects without skin lesions; 
** The difference is significant at 0.01 < p < 0.05 compared with subjects without skin lesions; 
* The difference is significant at 0.05 < p < 0.1 compared with subjects without skin lesion. 
3.3. Urinary Arsenic Metabolites among Men and Women  
The results in Table 3 show that the concentrations of TAs of women were significantly higher than 
that of men for the subjects without skin lesions. DMA
V of women were significantly higher than that 
of men, whether for the subjects with or without skin lesions. Women may have a higher recent arsenic 
exposure due to their roles as housewives in families. For the subjects without skin lesions, women 
had significantly lower percent iAs
III and percent MMA
V, but significantly higher percent DMA
V and 
SMI than men. On the other hand, for the subjects with skin lesions, significantly higher percent 
DMA
V  and  SMI  were  observed  in  women  than  in  men.  These  differences  suggested  that  arsenic 
methylation capability, especially the secondary methylation capability of women was higher than that 
of men. 
Table 3. Concentrations and percentages of arsenic species in urine of the men and women (N = 57). 
Metablates and 
Methylation index 
Men (n = 33)  Women (n = 24) 
Men without skin lesions 
(n = 9) GM (95% CI) 
Men with skin lesions 
(n = 24) GM (95% CI) 
Women without skin lesions 
(n = 12) GM (95% CI) 
Women with skin 
lesions 
(n = 12) GM (95% CI) 
TAs (μg/g Cr)  19.77 (13.27–29.46)  32.3
 c (25.53–40.86)  31.92
 ** (23.94–42.58)  47.5
 a,b (33.73–66.89) 
iAs
III (μg/g Cr)  1.97 (1.32–2.94)  3.24
 b (2.38–4. 4)  2.65 (1.91–3.69)  3.78 (2.56–5.57) 
MMA
V(μg/g Cr)  3.12 (1.98–4.92)  5.16
 c (3.95–6.74)  3.76 (2.89–4.89)  6.55
 a (4.67–9.17) 
DMA
V(μg/g Cr)  14.4 (9.78–21.19)  22.14
 c (17.64–27.8)  24.85
 ** (18.31–33.73)  35.49
 ** (25.02–50.33) 
iAs
V(μg/g Cr)  0.4 (0.21–0.76)  1.11
 a (0.76–1.6)  0.74
 * (0.52–1.05)  1.34
 b (0.77–2.35) 
Percent iAs
III (%)  9.96 (9.01–11.02)  10.03 (8.32–12.09)  8.31
 * (6.87–10.05)  7.95 (7.95–6.28) Int. J. Environ. Res. Public Health 2011, 8                 
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Table 3. Cont. 
Metablates and 
Methylation index 
Men (n = 33)  Women (n = 24) 
Men without skin lesions 
(n = 9) GM (95% CI) 
Men with skin lesions 
(n = 24) GM (95% CI) 
Women without skin lesions 
(n = 12) GM (95% CI) 
Women with skin 
lesions 
(n = 12) GM (95% CI) 
Percent MMA
V(%)  15.80 (13.23–18.87)  15.98
 α (14.21–17.96)  11.78 
** (9.53–14.57)  13.78 (11.84–15.97) 
Percent DMA
V(%)  72.81 (69.76–76.00)  68.55 
c,α (66.14–71.06)  77.85 
** (75.19–80.61)  74.70 
** (69.51–80.28) 
Percent iAs
V(%)  2.01 (1.33–3.04)  3.42 
c,β (2.58–4.54)  2.31 (1.66–3.21)  2.83 (1.75–4.56) 
PMI  1.48 (1.15–1.90)  1.20 (0.92–1.58)  1.29 (0.91–1.83)  1.49 (1.07–2.07) 
SMI  4.61 (3.73–5.69)  4.29
 α (3.76–4.90)  6.61 
** (5.20–8.39)  5.42 
** (4.45–6.61) 
Abbreviations: CI, confidence interval; Cr, creatinine; GM, geometric mean. 
**  The  difference  is  significant  at  0.01  <  p  <  0.05  compared  with  men; 
*  The  difference  is  significant  at  
0.05 < p < 0.1 compared with men; 
a  The  difference  is  significant  at  p  <  0.01  compared  with  subjects  without  skin  lesions; 
b  The  difference  is  
significant  at  0.01<p<0.05  compared  with  subjects  without  skin  lesions; 
c  The  difference  is  significant  at  
0.05 < p < 0.1 compared with subjects without skin lesions; 
α The  difference  is  significant  at  p  <  0.01  between  men  with  skin  lesions  and  women  without  skin  lesions; 
β The difference is significant at 0.05 < p < 0.1 between men with skin lesions and women without skin lesions. 
3.4. Relationship between Age and Urinary Arsenic Metabolites 
The Spearman’s correlation coefficients of Age/TAs (0.411), Age/iAs
III (0.343), Age/DMA
V (0.353), 
Age/MMA
V (0.439) and Age/iAs
V (0.422) were shown in Figure 3A–E. The figures shown that age 
was  positive  correlated  with  the  concentrations  of  TAs,  iAs
III,  DMA
V,  MMA
V  and  iAs
V.  These 
suggested that more arsenic may have been accumulated in the elder than in the younger. As regards 
arsenic methylation capability, the iAs
III percent, iAs
V percent, MMA
V percent, DMA
V percent, PMI 
and SMI did not reach statistical significance with age. (Figure 4). These suggested that the arsenic 
methylation capability may not correlated with age. 
Figure 3. Correlation of age with (A) TAs (R = 0.411, p = 0.001); (B) iAs
III (R = 0.343,  
p = 0.009); (C) iAs
V (R = 0.422, p = 0.001); (D) MMA
V (R = 0.439, p = 0.001); (E) DMA
V 
(R = 0.353, p = 0.007) in the urine. 
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Figure 3. Cont. 
 
Figure  4.  Correlation of age with (A) iAs
III percent (R = －0.06, p > 0.05); (B) iAs
V 
percent (R = 0.195, p > 0.05); (C) MMA
V percent (R = －0.17, p > 0.05); (D) DMA
V 
percent (R = －0.133, p > 0.05); (E) PMI (R = －0.021, p > 0.05); (F) SMI (R = －0.007,  
p > 0.05) in the urine. 
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Figure 4. Cont. 
 
3.5. Profiles of Urinary Arsenic Metabolites 
Based on population studies, the relative distributions of iAs, MMA
V and DMA
V in urine of various 
population groups seems to be fairly constant and in the range of 10–30%, 10–20% and 60–80%, 
respectively [9,27]. This study clearly showed that the percentages of arsenic species in urine were 
consistent with previously studies. However, it was documented that there were variations in arsenic 
methylation between population groups. A lower percent MMA in urine (in the range of 0.0–11%) of 
Atacamenos living in the Andes [28], whereas an unusual higher percent MMA in urine (20–30% on 
average) of people living in certain areas of Taiwan were also found [3,29]. The variation of arsenic 
metabolism between different population groups may be modulated by genetic polymorphism [29-31]. 
3.6. Arsenic Metabolism and Arsenic-Induced Skin Lesions 
Urinary arsenic is generally used as the main biomarker of exposure and is regarded as the most 
reliable indicator of recent exposure to inorganic arsenic [9]. However, it has been reported that dietary 
intake of seafood, containing high-level organic arsenicals such as arsenobetaine (AsB), arsenocholine 
(AsC)  and  arsenosugars,  which  are  regarded  as  non-toxic,  can  account  for  increases  of  DMA  in  
urine [32]. In this study area, seafood is rare in the diet because of the poor economic conditions and Int. J. Environ. Res. Public Health 2011, 8                 
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long distance from the sea. Therefore, it was feasible to take total urinary arsenic as a biomarker of 
exposure to inorganic arsenic. It was shown that the subjects with skin lesions had a higher urinary 
arsenic excretion (Table 2), indicating a higher recent arsenic exposure than subjects without skin 
lesions. Dose of arsenic exposure was an important factor being association with its health outcomes. 
A case-control study from the Black-foot-disease area in Taiwan found that cases with skin cancer had 
higher total urinary arsenic [33].  
The mechanisms of arsenic toxicity are not fully understood. In consideration of the end products in 
inorganic  arsenic  methylation  being  MMA
V  and  DMA
V,  which  are  less  reactive  with  tissue 
constituents and are more readily excreted in urine than inorganic arsenic [34], the methylation acts as 
a detoxification mechanism. However, the trivalent intermediates formed by reduction of MMA
V and 
DMA
V, namely MMA
III and DMA
III, are more toxic than arsenite [7], and have been found in human  
urine  [35,36].  Because  trivalent  arsenic  species  are  stronger  protein-binders  than  the  pentavalent  
species [37], MMA
III and DMA
III generated during the metabolism of arsenic in the cell are the species 
that interact with cytosolic proteins and may produce some of the toxic effects that accompany exposure 
to arsenic. Some scholars believe that various urinary arsenic metabolites may be associated with the 
individual susceptibility to clinical outcomes or diseases induced by arsenic exposure [2,34,37]. A pilot 
study conducted in Mexico found that the percentages of iAs and MMA
V in individuals with cutaneous 
symptoms were higher than those individuals with normal skin, while the percentage of DMA
V was 
lower [11]. In Bangladesh, a higher proportion of both inorganic arsenic and MMA
V and a lower 
proportion of DMA
V in urine were associated with a higher risk of skin lesions after adjusting for age, 
sex, socioeconomic status, tobacco use and cumulative arsenic exposure [1]. In Taiwan, an elevated 
urinary MMA
V proportion was associated with an increased risk of skin cancer [33]. These literatures 
from arsenism induced by arsenic polluted water consumption suggested that reduced methylation 
capability with increased percent MMA
V, decreased DMA
V, or decreased DMA
V/MMA
V (SMI) is 
associated with health outcomes of arsenic exposure. The result of this study conducted in a CAP area 
of China was consistent with these previous studies. The subjects with skin lesions had a lower arsenic 
methylation capability, as defined by a higher percent iAs and percent MMA
V and a lower percent 
DMA
V and SMI in urine than subjects without skin lesions, which suggested that arsenic methylation 
capability obviously have an effect on susceptibility to arsenic-induced skin lesions. 
It was documented that subjects with a lower percent MMA
V in urine may tend to have a lower 
retention and a faster elimination of ingested arsenic than those with a higher percent MMA
V [34]. 
Higher percent MMA
V and lower percent DMA
V in urine may be a result of inhibition of the second 
methylation step, which may increase the chances of cells to be exposed to the more toxic forms of 
MMA
III. It is possible that the higher MMA
V and lower DMA
V in urine are only a marker of higher 
MMA
III in the blood or inside the cells [37]. Besides, MMA
III could be oxidized into MMA
V rapidly 
under room temperature conditions [38]. Therefore, it is highly possible that a significant proportion of 
the measured MMA
V is actually derived from MMA
III. These could be possibly interpretations of 
people with a lower MMA
V and a higher percent DMA
V or a higher SMI tending to have a lower risk 
of developing arsenic induced disease. Int. J. Environ. Res. Public Health 2011, 8                 
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3.7. Differences of Arsenic Metabolism between Men and Women 
In this study, urinary arsenic in men and in women was compared (Table 3). A higher arsenic 
excretion in urine of women was observed and that may indicate a higher recent arsenic exposure of 
women. From the results of the face to face questionnaire, it was found that in Changshapu village 
women usually do housework and spend more time in the kitchen, while men usually cultivate the land 
and  spend  more  time  outdoors.  In  a  study  from  Shaanxi  Province,  it  was  observed  that  the 
concentrations of inorganic arsenic in the air of kitchen are higher than in outdoor air [13]. It was 
possible  that  women might have more chances to be exposed to arsenic than men do. Therefore, 
different roles in family taken by men and women might be the reason why the urinary arsenic of 
women was significantly higher than that of men. 
The  results  had  shown  that  the  distributions  of  arsenic  species  varied  widely  among  men  and 
women (Table 3). Women had a higher arsenic methylation capability than men in Changshapu village, 
as defined by significantly higher percent DMA
V and SMI in women’s urine. Many other studies have 
also suggested that the methylation capability of women was better than that of men [1,30,39,40]. This 
finding was consistent with the results from a study in Guizhou Province, another CAP epidemical 
area of China [41]. Shraim and his colleagues found that among 51 individuals exposed to arsenic 
through coal-burning, more than 30% of them had symptoms of arsenism and women had a higher 
percent DMA but a lower percent iAs in urine. This difference of arsenic methylation capability may 
be explained by the effect of estrogen. It was believed that estrogens involved in arsenic methylation 
protect against the skin effects of arsenic [1]. Compared to men, the efficient methylation of arsenic in 
women might be related to the higher production of choline, which was then oxidized into betaine, the 
sole alternate methyl group to folate for the remethylation of homocysteine to methionine [42,43]. 
Elevated homocysteine levels, indicative of a lower one-carbon metabolism, were associated with less 
efficient methylation of arsenic [40]. Another possible reason for less efficient arsenic methylation in 
men might be attributed to that men might be exposed to more hazard factors such as smoking [44,45]. 
According to an epidemiologic investigation conducted in the CAP area in Shaanxi Province, the 
prevalence of skin lesions in women was lower than men (women vs. men: 16.57% and 21.61%,  
p < 0.05) [19]. In this study, it seemed paradoxical but interesting that women had higher urinary 
arsenic concentrations but lower susceptibility to skin lesions than men. It was shown in Table 3 that 
similar TAs concentrations were observed in men with skin lesions and women without skin lesions 
(men with skin lesions: 32.3 μg/g Cr, women without skin lesions: 31.92 μg/g Cr; p > 0.1), suggesting 
that the two groups had well-matched arsenic exposures; but arsenic exposure induced skin lesions in 
men but did not in women. These data suggested that men showed symptoms of poisoning before 
women under the same arsenic exposure and that men were more susceptible than women to arsenism. 
Studies  from  Bangladesh,  Taiwan  and  India  had  all  reported  that  men  were  more  susceptible  to 
arsenic-related skin effects than women [46-49]; however, the interpretations were not very clear. 
Lindberg and his colleagues investigated the interaction between gender and arsenic metabolism for 
the  risk  of  developing skin lesions and established a hypothesis for the first time that the  higher 
prevalence of arsenic-related skin lesions among men may be mainly attributed to the less efficient of 
arsenic metabolism among men [1]. In Table 3, women without skin lesions had lower percent MMA
V 
and percent iAs
V, but higher percent DMA
V and SMI than men with skin lesions, indicating that the Int. J. Environ. Res. Public Health 2011, 8                 
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arsenic methylation capability, particularly the second arsenic methylation capability of women was 
markedly higher than that of men. These findings approved the hypothesis of Lindberg that women 
with higher arsenic exposure being less susceptible to skin lesions induced by coal arsenic exposure 
than men may be explained by the more efficient arsenic methylation of women, as defined by their 
higher percent DMA
Vand SMI in the urine of women. 
3.8. Arsenic Excretion and Metabolism in Different Age 
In  this  study,  the  content  of  arsenic  in  urine  increased  with  age,  and  the  arsenic  methylation 
capability was not correlated with age. Age may be associated with arsenic metabolism. A study in 
Taiwan suggested that a decrease in the second methylation capability may be associated with the 
increasing  of  age  [50].  A  similar  diminishing  capability  with  age  was  also  observed  by  other 
investigators [3,33]. On the other hand, a case-control study conducted in Taiwan to evaluate the 
association  between  exposure  to  low  arsenic  levels  and  urothelial  cancer  observed  no  association 
between age and any of the urinary arsenic indices in patients with urothelial cancer [39]. Aging was 
negatively associated with SMI in residents of northern Chile, but was not significant when the effect 
of length of residence in the contaminated area was adjusted [9]. In this study, the residents living in 
Changshapu  had  been  exposed  to  arsenic  since  they  were  born.  The  time  of  duration  of  arsenic 
exposure significantly affected the amount of cumulative arsenic exposure. However, the cumulative 
arsenic  exposure  did  not  directly  affect  arsenic  methylation  metabolism.  Therefore,  we  could  not 
determine whether there was relationship between age and arsenic methylation interfered by the duration 
time of arsenic exposure. Furthermore, aging may be associated with a variety of functional changes 
(such as the liver and kidney) in the organs involved in the metabolism or retention of the metabolites of 
arsenic [51]. 
3.9. Limitations to the Present Study 
Limitations to the present study include the small sample size. Both the use of spot urine samples 
and the storage of urine samples limited the size of the present sample, and this raises the possibility 
that findings may have been attributed to chance and hence need to be replicated. However, our sample 
size is comparable to those of numerous other studies of urinary arsenic metabolism [52,53]. Second, 
the  other  important  risk  factors  related  with  skin  lesions  such  as  assets  and  education  were  not 
mentioned in present study, because each person’s assets and education are similar in this poor small 
village. In future work, we will solve these limitations. 
4. Conclusions  
Subjects  with  skin  lesions  had  a  higher  concentration  of  urinary  arsenic  and  a  lower  arsenic 
methylation capability than subjects without skin lesions. Not only the dose of arsenic exposure but 
also the arsenic methylation capability had an impact on the individual susceptibility to skin lesions 
induced by coal arsenic exposure. It was found that the capability for inorganic arsenic methylation is 
modified by sex. The lower susceptibility to skin lesions in women than in men was mainly explained 
by the more efficient methylation of arsenic, as defined by a higher percent DMA
V and SMI in urine Int. J. Environ. Res. Public Health 2011, 8                 
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among women. Further studies with more larger sample sizes, study protocols and consideration of 
potential confounders need to be done in the future. 
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